While most recent studies have focused on checkpoint blockade14,26, more attention should be paid to the increased Tregs inside the tumor microenvironment (TME) that limit IL-2 binding to and subsequent stimulation of CTLs. The gene discussed is IL2; the disease is neoplasm.